Akebia Therapeutics Inc.

10/26/2026 | Press release | Distributed by Public on 10/26/2026 07:29

U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Akebia Therapeutics Inc. published this content on October 26, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 26, 2026 at 13:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]